A vaccine directed against tumor blood vessels suppress tumor growth and metastasis

The target molecule of the immunization strategy is the extra domain-A (ED-A) of fibronectin, a protein domain which is highly selective for the tumor vasculature in the adult.

“The vaccination approach we have employed is not prophylactic but therapeutic, meaning that immunity was induced after the onset of tumorigenesis – a scenario that resembles the clinical conditions much more closely than prophylactic immunization studies, says Anna-Karin Olsson, researcher at the Department of Medical Biochemistry and Microbiology at Uppsala University”, who has led the study.

The therapeutic effect was significant, despite the aggressive nature of the tumor model. Moreover, the vaccine induced an 80 percent reduction metastasis, which is an important finding considering that a majority of all deaths by cancer are caused by cancer that has spread in the body.

A major advantage of the approach is that the target molecule ED-A is present in the majority of solid tumors. Vaccination against ED-A could therefore provide a treatment strategy with broad applications in cancer therapy. Furthermore, the researchers show that their strategy for immunization against a self-molecule is highly efficient and can be achieved with an adjuvant (immunostimulatory compound included in vaccines) that is acceptable for use in the clinic. The lack of potent, but at the same time non-toxic and biodegradable adjuvants has been a major limitation in the development of therapeutic vaccines.

Another important aspect is that therapeutic vaccination (endogenous production of the target antibodies) can provide a cost-efficient alternative to administration of large amounts of monoclonal antibodies, currently in clinical use for cancer and other diseases. The high costs associated with monoclonal antibody-based therapies puts a significant strain on the health-care economy, which may limit accessibility for patients.

“In conclusion, we believe therapeutic vaccination could provide a new, potent and cost-efficient treatment strategy for solid tumors and metastasizing cancer”, says Anna-Karin Olsson.

For more information, please contact Anna-Karin Olsson, tel: +46-18 471 4399 or +46-730 573013 or e-mail: Anna-Karin.Olsson@imbim.uu.se

Referens:
“Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer”, Julia Femel, Elisabeth JM Huijbers, Falk Saupe, Jessica Cedervall, Lei Zhang, Pernilla Roswall, Erik Larsson, Helena Olofsson, Kristian Pietras, Anna Dimberg, Lars Hellman and Anna-Karin Olsson

Media Contact

Anna-Karin Olsson EurekAlert!

All latest news from the category: Studies and Analyses

innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.

Back to home

Comments (0)

Write a comment

Newest articles

Distance learning can improve women’s access to vocational training as animal health care practitioners in Nepal. Image Credit: Heifer International

Hybrid Job Training Boosts Women’s Participation in Nepal

Globally, women’s workforce participation is about 25% lower than men’s, often due to barriers such as domestic responsibilities and cultural norms. Vocational training can increase employment opportunities, but women may…

CO2release increase under repeated drying-rewetting cycles (DWCs). Image Credit: Suzuki, Nagano et al., 2025 SOIL

Drying and Rewetting Cycles Boost Soil CO2 Emissions

Niigata, Japan – The amount of carbon dioxide (CO2) released by microbial decomposition of soil organic carbon on a global scale is approximately five times greater than the amount of…

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers. Oregon State's Olena Taratula and collaborators including OSU postdoctoral researcher Babak Mamnoon and Maureen Baldwin, a physician at Oregon Health & Science University, designed a type of drug nanocarrier known as a polymersome to specifically target a protein in choriocarcinoma cells. Depicted is a polymersome with its methotrexate cargo. Illustration by Parinaz Ghanbari. Image Credit: Parinaz Ghanbari

Improved Treatment Method for Rare Pregnancy-Related Cancer

PORTLAND, Ore. – A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other…